Search Results

Endonovo Therapeutics, Inc. announced the retention of Ocean Tomo, a part of J.S. Held, to conduct a fairness opinion analysis in connection with the proposed spin-off of Endonovo’s medical device assets to a newly formed Delaware company, SofPulse, Inc.

Ocean Biomedical (NASDAQ: OCEA ) announced today that Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been granted a new patent for his malaria therapeutic antibody discoveries, targeted to both prevent malaria infection and treat severe malaria.

Accuray Incorporated announced that the registration dossier for the CNNC-Accuray joint venture Tomo® C radiation therapy system for the Type B market has been approved by the Chinese National Medical Products Administration.

XVIVO Perfusion AB The Lancet reports that for the first time in medical history, transportation of a donor heart has been performed across the Atlantic Ocean.

Ocean Biomedical, Inc., announced that on April 18, 2024, it received a notice from The Nasdaq Stock Market LLC stating that because the Company has not yet filed its Annual Report on Form 10-K for the period ended December 31, 2023, the Company is not in compliance with Nasdaq Listing Rule 5250, which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission.